Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma.

ABSTRACT: Hepatocellular carcinoma is a common gastrointestinal malignancy with a high mortality rate and limited treatment options. Molecularly targeted drugs combined with immune checkpoint inhibitors have shown unique advantages over single-agent applications, significantly prolonging patient survival. This paper reviews the research progress of molecular-targeted drugs combined with immune checkpoint inhibitors in the treatment of hepatocellular carcinoma and discusses the effectiveness and safety of the combination of the two drugs to provide a reference for the further application of molecular-targeted drugs combined with immune checkpoint inhibitors in clinical practice.

SUBMITTER: Xie S 

PROVIDER: S-EPMC10248438 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature